Survival with docetaxel plus capecitabine comparing with vinorelbine plus capecitabine followed by capecitabine maintenance treatment as first-line therapy in patients with advanced breast cancer: A phase III randomized clinical trial

被引：0
|
作者：
Xu, Binghe
Wang, Jiayu
Li, Qing
Zhang, Pin
Yuan, Peng
Ma, Fei
Cai, Ruigang
Fan, Ying
Luo, Yang
Li, Qiao
机构：
[1] Chinese Acad Med Sci, Canc Hosp, Beijing 100730, Peoples R China
[2] Chinese Acad Med Sci, Canc Hosp & Inst, Beijing 100730, Peoples R China
[3] Peking Union Med Coll, Beijing 100021, Peoples R China
[4] Chinese Acad Med Sci, Canc Inst & Hosp, Dept Med Oncol, Beijing 100730, Peoples R China
[5] Chinese Acad Med Sci, Canc Hosp, Dept Med Oncol, Beijing 100730, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.1049
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1049
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A randomized phase II trial comparing capecitabine with oxaliplatin or docetaxel as first-line treatment in advanced gastric and gastroesophageal adenocarcinomas
    Ni, Lu
    Zhang, Weihan
    Chen, Ye
    Leng, Weibing
    Gou, Hongfeng
    Hu, Jiankun
    Qiu, Meng
    MEDICINE, 2021, 100 (17) : E25493
  • [32] Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results
    Michalaki, Vasiliki
    Gennatas, Spyridon
    Gennatas, Konstantine
    ANTI-CANCER DRUGS, 2009, 20 (03) : 204 - 207
  • [33] Activity and safety of vinorelbine and capecitabine as first-line treatment in patients with metastatic breast cancer - a phase II trial
    Palumbo, R.
    Bernardo, A.
    Strada, M.
    Teragni, C.
    Poggi, G.
    Frascaroli, M.
    Amatu, A.
    Palumbo, I.
    Bernardo, G.
    EJC SUPPLEMENTS, 2008, 6 (07): : 177 - 177
  • [34] A Phase II Study of Sequential Capecitabine Plus Oxaliplatin Followed by Docetaxel Plus Capecitabine in Patients With Unresectable Gastric Adenocarcinoma The TCOG 3211 Clinical Trial
    Chen, Ming-Huang
    Lin, Johnson
    Hsiao, Chin-Fu
    Shan, Yan-Shen
    Chen, Yeu-Chin
    Chen, Li-Tzong
    Liu, Tsang-Wu
    Li, Chung-Pin
    Chao, Yee
    MEDICINE, 2016, 95 (03) : 1 - 6
  • [35] Phase II trial of first-line capecitabine plus cisplatin in patients with advanced/metastatic nasopharyngeal cancer (NPC)
    Chua, D.
    Ng, W.
    Yiu, H.
    Seetalarom, K.
    Kurnianda, J.
    Sze, W.
    Krishnan, G.
    Shotelersuk, K.
    Hong, R.
    Forster, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [36] Phase II trial of oxaliplatin plus oral capecitabine as first-line chemotherapy for patients with advanced gastric cancer
    Yang, Tingsong
    Shen, Xiaojun
    Tang, Xiaojun
    Wei, Guo
    Zhang, Hao
    Du, Chenghui
    Xue, Xuchao
    Ma, Liye
    Nie, Mingming
    Bi, Jianwei
    TUMORI, 2011, 97 (04) : 466 - 472
  • [37] First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer
    Park, SH
    Bang, SM
    Cho, EK
    Baek, JH
    Oh, JH
    Im, SA
    Park, YS
    Shin, DB
    Lee, JH
    ONCOLOGY, 2004, 66 (05) : 353 - 357
  • [38] First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer
    Michalaki, V.
    Gennatas, C.
    Gennatas, S.
    Vasiliou, J.
    Smyrniotis, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [39] Irinotecan plus capecitabine as first-line chemotherapy in advanced colorectal cancer
    Gennatas, C.
    Michalaki, V.
    Gennatas, S.
    Papalambros, E.
    ANTICANCER RESEARCH, 2008, 28 (3B) : 1923 - 1926
  • [40] Irinotecan plus capecitabine as first-line chemotherapy in advanced colorectal cancer
    Michalaki, V.
    ANNALS OF ONCOLOGY, 2008, 19 : I45 - I45
12345